| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer
|
Rustin, G.
|
|
|
22 |
11 |
p. 2411-2416
|
artikel
|
| 2 |
Aspirin use and risk for lung cancer: a meta-analysis
|
Oh, S.-W.
|
|
|
22 |
11 |
p. 2456-2465
|
artikel
|
| 3 |
A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices
|
Pisters, P.W.T.
|
|
|
22 |
11 |
p. 2523-2529
|
artikel
|
| 4 |
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study
|
Weberpals, J.I.
|
|
|
22 |
11 |
p. 2403-2410
|
artikel
|
| 5 |
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?
|
Kelly, C.M.
|
|
|
22 |
11 |
p. 2387-2393
|
artikel
|
| 6 |
Correction to: Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer
|
|
|
|
22 |
11 |
p. 2537
|
artikel
|
| 7 |
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer
|
Bossi, P.
|
|
|
22 |
11 |
p. 2495-2500
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
22 |
11 |
p. ii-iii
|
artikel
|
| 9 |
Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group
|
Pallis, A.G.
|
|
|
22 |
11 |
p. 2448-2455
|
artikel
|
| 10 |
Evaluating the risk–benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas
|
Rodrigues, M.J.
|
|
|
22 |
11 |
p. 2530
|
artikel
|
| 11 |
GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients
|
Winder, T.
|
|
|
22 |
11 |
p. 2431-2439
|
artikel
|
| 12 |
Is adjuvant chemotherapy useful in lobular breast cancer patients?
|
Liem, X.
|
|
|
22 |
11 |
p. 2532-2533
|
artikel
|
| 13 |
Metaplastic carcinoma with extensive dendritic cell differentiation: a previously unrecognised type of triple-negative breast cancer
|
Cesinaro, A.M.
|
|
|
22 |
11 |
p. 2531-2532
|
artikel
|
| 14 |
Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer
|
Chu, D.
|
|
|
22 |
11 |
p. 2440-2447
|
artikel
|
| 15 |
Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer
|
Masuda, S.
|
|
|
22 |
11 |
p. 2533-2534
|
artikel
|
| 16 |
Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis
|
Teuffel, O.
|
|
|
22 |
11 |
p. 2358-2365
|
artikel
|
| 17 |
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
|
Kurtz, J.E.
|
|
|
22 |
11 |
p. 2417-2423
|
artikel
|
| 18 |
Palliative chemotherapy during the last month of life
|
Näppä, U.
|
|
|
22 |
11 |
p. 2375-2380
|
artikel
|
| 19 |
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)
|
Barlesi, F.
|
|
|
22 |
11 |
p. 2466-2470
|
artikel
|
| 20 |
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
|
Yong, W.P.
|
|
|
22 |
11 |
p. 2516-2522
|
artikel
|
| 21 |
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors
|
Langenberg, M.H.G.
|
|
|
22 |
11 |
p. 2508-2515
|
artikel
|
| 22 |
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
|
Fléchon, A.
|
|
|
22 |
11 |
p. 2476-2481
|
artikel
|
| 23 |
Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung
|
Naito, Y.
|
|
|
22 |
11 |
p. 2471-2475
|
artikel
|
| 24 |
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)
|
Pinto, C.
|
|
|
22 |
11 |
p. 2424-2430
|
artikel
|
| 25 |
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck
|
Villaflor, V.M.
|
|
|
22 |
11 |
p. 2501-2507
|
artikel
|
| 26 |
Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer
|
Argiris, A.
|
|
|
22 |
11 |
p. 2482-2488
|
artikel
|
| 27 |
Postoperative elective nodal irradiation for squamous cell carcinoma of the head and neck: outcome and prognostic factors for regional recurrence
|
Vergeer, M.R.
|
|
|
22 |
11 |
p. 2489-2494
|
artikel
|
| 28 |
Reply to Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer
|
Chu, D.
|
|
|
22 |
11 |
p. 2534
|
artikel
|
| 29 |
Retraction
|
|
|
|
22 |
11 |
p. 2536
|
artikel
|
| 30 |
Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer
|
Chavez-MacGregor, M.
|
|
|
22 |
11 |
p. 2394-2402
|
artikel
|
| 31 |
Table of Contents
|
|
|
|
22 |
11 |
p. iv-v
|
artikel
|
| 32 |
The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis
|
Balagula, Y.
|
|
|
22 |
11 |
p. 2366-2374
|
artikel
|
| 33 |
The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy
|
Geffen, D.B.
|
|
|
22 |
11 |
p. 2381-2386
|
artikel
|
| 34 |
Thymic large-cell neuroendocrine carcinoma: a disease neglected in the ESMO guideline?
|
Shoji, T.
|
|
|
22 |
11 |
p. 2535
|
artikel
|
| 35 |
Today's lifestyles, tomorrow's cancers: trends in lifestyle risk factors for cancer in low- and middle-income countries
|
McCormack, V.A.
|
|
|
22 |
11 |
p. 2349-2357
|
artikel
|
| 36 |
Why do our patients get chemotherapy until the end of life?
|
Braga, S.
|
|
|
22 |
11 |
p. 2345-2348
|
artikel
|
Tijdschrift beschrijving